Pliant Therapeutics (PLRX) Stock
Clinical stage biotech developing fibrotic disease therapies. Here's the price, business snapshot, and what's worth knowing about Pliant Therapeutics in November 2026.
Pliant Therapeutics (PLRX) is a clinical‑stage biotechnology company focused on developing therapies for fibrotic diseases. With a market capitalisation around $115m, it sits in the small‑cap, high‑volatility segment of healthcare. Investors should know the company’s value is driven largely by clinical progress and trial readouts rather than current revenues; successful trial data or partnerships can be significant catalysts, while negative results or funding shortfalls can materially depress the share price. Typical risks include long development timelines, regulatory uncertainty, potential dilution from future financings and the binary nature of clinical outcomes. This summary is for educational purposes and not investment advice — investors should review regulatory filings, recent trial updates, cash runway and analyst commentary, and consider suitability with their objectives and risk tolerance before making decisions.
Pliant Therapeutics (PLRX) Stock Forecast
Analyst price target, next 12 months
$40.80
+4541.1% vs today's $0.88
Price range over the last 12 months
Close to its 12-month low
Analysts covering Pliant Therapeutics have a consensus 12-month target of $40.80, above the current price of $0.88.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 29 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Pliant Therapeutics' stock with a target price of $40.8, indicating potential growth.
Financial Health
Pliant Therapeutics is generating good profits and cash flow, indicating a strong financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PLRX
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: 19 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical‑stage focus
Programmes are at the clinical development stage, so trial readouts and regulatory steps are key catalysts — though results can be binary and unpredictable.
Fibrosis market potential
Fibrotic diseases represent a significant unmet medical need, offering potential upside if therapies prove effective, while commercial success is far from guaranteed.
Capital and timing
As a small‑cap company with a market cap ~ $115m, funding rounds and partnerships can change the outlook; investors should consider runway and dilution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
